TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00904982

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Financial Incentive and Med-eMonitor
Description: Financial Incentives: Study participants are entered into a daily lottery. It includes a chance to win either $10 or $100 on any given day throughout the participant's duration in the study (6 months). Participants are assigned a number and each day a computer randomly draws a winning number. Participants whose number is drawn can only collect money if they have taken the medication correctly.~Med-eMonitor: The Med-eMonitor is a device used to measure medication compliance. The device has 5 drawers in which the participants' medication is placed. When a drawer opens, a message displays on the monitor, and asks the participant if he/she is taking his/her medication for the day. The device registers their answers and sends the compliance information via the participants' telephone line nightly to a central study server.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive and Med-eMonitor
Description: Financial Incentives: Study participants are entered into a daily lottery. It includes a chance to win either $10 or $100 on any given day throughout the participant's duration in the study (6 months). Participants are assigned a number and each day a computer randomly draws a winning number. Participants whose number is drawn can only collect money if they have taken the medication correctly.~Med-eMonitor: The Med-eMonitor is a device used to measure medication compliance. The device has 5 drawers in which the participants' medication is placed. When a drawer opens, a message displays on the monitor, and asks the participant if he/she is taking his/her medication for the day. The device registers their answers and sends the compliance information via the participants' telephone line nightly to a central study server.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive and Med-eMonitor
Description: Financial Incentives: Study participants are entered into a daily lottery. It includes a chance to win either $10 or $100 on any given day throughout the participant's duration in the study (6 months). Participants are assigned a number and each day a computer randomly draws a winning number. Participants whose number is drawn can only collect money if they have taken the medication correctly.~Med-eMonitor: The Med-eMonitor is a device used to measure medication compliance. The device has 5 drawers in which the participants' medication is placed. When a drawer opens, a message displays on the monitor, and asks the participant if he/she is taking his/her medication for the day. The device registers their answers and sends the compliance information via the participants' telephone line nightly to a central study server.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2Med-eMonitor
Description: Med-eMonitor is a device that subjects will be given that will monitor an individual's warfarin adherence.
Study: NCT01651156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: oral taken

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02294708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: postoperative postures
Description: two postoperative postures: supine and temporal-lateral

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: postoperative postures
Description: two postoperative postures: supine and temporal-lateral
Study: NCT03104907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatic Artery Embolization
Description: The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
Study: NCT02574117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: flap with corticotomy and bone allograft
Description: A maxillary expansion with quad helix appliance was placed on the posterior teeth with cross bite. A Luebke buccal flap was opened in the area of maxillary 1st premolar, 2nd premolar and first molar with a no. 15 scalpel. Corticotomy procedure was performed using low speed round bur size 3, holes to create a 0.5 mm deep hole penetrating the cortical bone. Multiple holes were performed leaving 1.5 mm distance in between. The defects were covered with demineralized freeze-dried bone allograft and the flap was sutured in its original position with 3-0 black silk suture.
Study: NCT02420821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Days 1 and 22 of each 42-day cycle.
Study: NCT00420433

Intervention type: PROCEDURE
Intervention: Radiography
Description: Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.

Intervention type: PROCEDURE
Intervention: CT Scan
Description: CT scan will include your chest, abdomen, and pelvis. Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
Study: NCT04647045

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cultured milk drink
Description: Each bottle contains 109 cfu Lactobacillus acidophilus LA-5 and Lactobacillus paracasei L. CASEI-01. In each 100 ml unit, it contains 4.06 g of fructose, 4.14 g of glucose, 0.29 g of sucrose, less than 0.1 g of maltose and 1.35 g of lactose.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Cultured milk drink
Description: Each bottle contains 109 cfu Lactobacillus acidophilus LA-5 and Lactobacillus paracasei L. CASEI-01. In each 100 ml unit, it contains 4.06 g of fructose, 4.14 g of glucose, 0.29 g of sucrose, less than 0.1 g of maltose and 1.35 g of lactose.
Study: NCT04433585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT02001610

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acidophilus pearls
Description: * Acidophilus pearls are encapsulated using patented process~* Subjects take one capsule (containing at least 1 x 10\^9 colony forming units) every morning for 12 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hard shell gelatin capsules
Description: * Hard-shelled gelatin capsule with same microbial formulation as pearl supplement~* Subjects consume one capsule (containing at least 1 x 10\^9 colony forming units) every morning for 12 days
Study: NCT03005860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2,6-Diisopropylphenol
Description: In Propofol group, anesthesia will be induced with Propofol TCI using Schneider model to achieve a target site concentration of 4 - 6 mcg/ml. Propofol TCI to achieve BIS (Bispectral Index) between 40-60.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoromethyl hexafluoroisopropyl ether
Description: In Sevoflurane group, anesthesia will be induced with 5 - 7mg/kg thiopental, maintenance with O2 with air 50:50%, sevoflurane 2-2.5 %, Further fentanyl, in increments of 1 mcg/kg - and atracurium 0.15 mg/kg, will be given as indicated by the clinical signs and hemodynamic changes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate
Description: Inj. fentanyl 2 mcg/kg will be used as an adjunct during anaesthetic induction.
Study: NCT02420821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 22 of each 42-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Sunitinib will be administered at a dose of 50 mg once daily, orally via capsule, on Day 1 through Day 28 of each 42-day cycle.
Study: NCT02787902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication
Description: Behavioral weight management program adapted for mother-daughter dyads with communication skills training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Behavioral weight management program adapted for mother-daughter dyads without communication skills training
Study: NCT01812863

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Supraclavicular nerve block
Description: Following injection of morphine, an ultrasound-guided supraclavicular nerve catheter (Angiocath) will be placed in Group 2. All catheters will be placed by one of the anesthesiologist trained in regional pain control using a 25 mm linear US probe in a sterile fashion.~If the examination is unchanged from preoperative assessment, an injection block using 5 ml of 0.25% bupivacaine with 1:200,000 epinephrine will be administered. Bupivacaine is a long acting local anesthetic that prevents nerve conduction and action potential initiation by decreasing the permeability of the neuronal membrane to sodium. We use a maximum dose of 5 mL of 0.25% bupivacaine, and we usually base the dose on a ml/kg (0.2 ml/kg) with a maximum dose not to exceed 2.5 mg/kg. This will be well below toxic levels.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supraclavicular nerve block
Description: Following injection of morphine, an ultrasound-guided supraclavicular nerve catheter (Angiocath) will be placed in Group 2. All catheters will be placed by one of the anesthesiologist trained in regional pain control using a 25 mm linear US probe in a sterile fashion.~If the examination is unchanged from preoperative assessment, an injection block using 5 ml of 0.25% bupivacaine with 1:200,000 epinephrine will be administered. Bupivacaine is a long acting local anesthetic that prevents nerve conduction and action potential initiation by decreasing the permeability of the neuronal membrane to sodium. We use a maximum dose of 5 mL of 0.25% bupivacaine, and we usually base the dose on a ml/kg (0.2 ml/kg) with a maximum dose not to exceed 2.5 mg/kg. This will be well below toxic levels.
Study: NCT03530982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive goal training
Description: Intensive goal training : 30 hours during 2 weeks
Study: NCT01016249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment 1. (5% Hypertonic saline + Epinephrine)
Description: Nebulization of 4ml 5% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment 3. (3% Hypertonic saline + Epinephrine)
Description: Nebulization of 4ml 3% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment 2. (Normal saline + Epinephrine)
Description: Nebulization of 4ml 0.9% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
Study: NCT02277938

Intervention type: DRUG
Intervention: Amantadine
Description: Amantadine is a drug that has been on the market for several years and is currently approved for the treatment of Parkinson's disease and for prevention against influenza A infection. Amantadine may be of value in detecting the presence of cancer.
Study: NCT02911844

Intervention type: DRUG
Group type: OTHER
Intervention: Fulvestrant
Description: Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.
Study: NCT03842527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Gastric ultrasound of the stomach antrum to assess contents 1 hour prior to C-section surgery. Scans will be completed in both supine (lying on back) and right lateral decubitus (positions) positions. The completion of both scans will take 5-10 minutes total

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Gastric ultrasound of the stomach antrum to assess contents 1 hour prior to C-section surgery. Scans will be completed in both supine (lying on back) and right lateral decubitus (positions) positions. The completion of both scans will take 5-10 minutes total
Study: NCT02875236

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OctaplasLG®
Description: OctaplasLG is an donor plasma product pooled from approximately 1000 single donor units. It possesses unique features when compared to standard fresh frozen plasma, such as having standardized concentrations of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen free. The manufacturing method of OctaplasLG removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation by immune neutralization. OctaplasLG should reduce the inflammatory hit on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer-acetat
Description: Crystalloid used as standard of care.
Study: NCT05323227

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CTA
Description: Patients receive coroanry CTA at the discretion of the physicians in charge. And parameters including plaque burden, minimal lumen area, diameter stenosis, total plaque volume, high-risk plaque characteristics, fractional flow reserve, pullback pressure gradient, fat attenuation index will be analyzed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CTA
Description: Patients receive coroanry CTA at the discretion of the physicians in charge. And parameters including plaque burden, minimal lumen area, diameter stenosis, total plaque volume, high-risk plaque characteristics, fractional flow reserve, pullback pressure gradient, fat attenuation index will be analyzed.
Study: NCT06276829

Intervention type: DIAGNOSTIC_TEST
Intervention: LDH/albumin ratio
Description: LDH/Albumin ratios of patient and control groups were recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: LDH/albumin ratio
Description: LDH/Albumin ratios of patient and control groups were recorded.
Study: NCT01236209

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Webpage
Description: one arm having access to a webpage with information about coping with pain and relaxation exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Webpage and situation feedback
Description: having access to the same web-page with information about coping with pain and relaxation relaxation and completing 3 diaries and receiving situational feedback for 4 weeks at home through a web enabled mobile phone.
Study: NCT00454324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given at a dose of target area under the concentration versus time curve in mg/mL•min (AUC)=6, on Day 1 of a 21 Day Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given at a dose of target area under the concentration versus time curve in mg/mL•min (AUC)=6, on Day 1 of a 21 Day Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane will be given at a dose of 240mg/m2 on Day 1 of a 21 Day Cycle (Arm A)~Abraxane will be given at a dose of 80mg/m2 on Days 1, 8, and 15 of a 21 Day Cycle (Arm B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane will be given at a dose of 240mg/m2 on Day 1 of a 21 Day Cycle (Arm A)~Abraxane will be given at a dose of 80mg/m2 on Days 1, 8, and 15 of a 21 Day Cycle (Arm B)
Study: NCT02784548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Using a VR headset, motion sensors, and VR software, the investigators will create a customized VR treatment for each participant that engages them in movements and exercises involving their missing limb in a game-like environment. For example, participants may use the headset to engage in activities such as driving a race car around a course requiring both arms, ski down simulated slopes, or manipulate objects.
Study: NCT03133793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CoQ10
Description: Participants will take 300 mg capsules two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CoQ10
Description: Participants will take 300 mg capsules two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Ribose Oral Powder
Description: Participants will mix 15 grams D-Ribose powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Ribose Oral Powder
Description: Participants will mix 15 grams D-Ribose powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pills
Description: Participants will take matched placebo pills that are 300 mg capsules, two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: Participants will take matched placebo pills that are 300 mg capsules, two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo powder
Description: Participants will mix 15 grams placebo powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: Participants will mix 15 grams placebo powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
Study: NCT00888134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study: NCT04139018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol Gel
Description: Timolol nasal gel 0.1% will be prepared with a poloxamer gel (combination of poloxamer 188 and 407; pH adjusted to 4.5-6.5) and 0.5 ml applied to each nostril twice daily. The total daily dose would amount to 2 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Placebo gel is prepared with poloxamers and no active ingredients.
Study: NCT03005860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: Inj. fentanyl 2 mcg/kg will be used as an adjunct during anaesthetic induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atracurium Besylate
Description: Inj. atracurium 0.5 mg/kg for will be administered for facilitating LMA placement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium Besylate
Description: Inj. atracurium 0.5 mg/kg for will be administered for facilitating LMA placement
Study: NCT04187989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Intervention
Description: Information will be posted by e-coaches. You can interact with the e-coaches as well as other study members in your group.
Study: NCT03064035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-factor prothrombin complex concentrate (4FPCC)
Description: 4-factor prothrombin complex concentrate (4FPCC) contains all of the vitamin K-dependent clotting factors inhibited by warfarin, making it desirable for use in warfarin reversal for emergent bleeds. Multiple guidelines currently recommend 4FPCC for warfarin reversal in vitamin K-dependent major bleeding or intracranial hemorrhage. 4FPCC has a fast onset of action and has demonstrated significant reversal of INR within 10 minutes. Its duration of action is up to 8 hours, and for this reason it should be given concurrently with vitamin K. Vitamin K has a delayed onset of action due to its need to stimulate the synthesis of clotting factors so its effects begin as the effects of 4FPCC diminish. 4FPCC is the standard of care treatment for this clinical population in the Regions Hospital Emergency Department.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4-factor prothrombin complex concentrate (4FPCC)
Description: 4-factor prothrombin complex concentrate (4FPCC) contains all of the vitamin K-dependent clotting factors inhibited by warfarin, making it desirable for use in warfarin reversal for emergent bleeds. Multiple guidelines currently recommend 4FPCC for warfarin reversal in vitamin K-dependent major bleeding or intracranial hemorrhage. 4FPCC has a fast onset of action and has demonstrated significant reversal of INR within 10 minutes. Its duration of action is up to 8 hours, and for this reason it should be given concurrently with vitamin K. Vitamin K has a delayed onset of action due to its need to stimulate the synthesis of clotting factors so its effects begin as the effects of 4FPCC diminish. 4FPCC is the standard of care treatment for this clinical population in the Regions Hospital Emergency Department.
Study: NCT01111474

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cyanoacrylate
Description: 3 applications of cyanoacrylate (48 hours interval) at the cervical region of the sensitive tooth

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: This process was conducted three times with an interval of 48 hours between applications, according to laser's manufacturer advice Clean Line Easy Laser - LILT®, Clean Line Easy Laser Doctor Dental Products Industry LTDA, BRA). For dentin hypersensitivity, the application of 1Joule/cm\^2 is recommended for eight seconds at three points along the dental neck, using the infrared wavelength (795nm).
Study: NCT01690312

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of fish oil \[620 mg of DHA and 150 mg of EPA\], providing a total daily dosage of 4000 mg of fish oil \[3080 mg of DHA+EPA\].

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.